Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

Recommended Dose of Pembrolizumab Plus Cabozantinib Combo Induced Response in mRCC

June 9, 2021
By Caroline Seymour
Article
Conference|ASCO Annual Meeting: Genitourinary

The recommended phase 2 dose of pembrolizumab plus cabozantinib induced a response with a manageable safety profile for patients with mRCC.

For over half of the patients with metastatic renal cell carcinoma (mRCC), the recommended phase 2 dose (RP2D) of pembrolizumab (Keytruda) plus cabozantinib (Cabometyx) induced a response with a manageable safety profile, meeting the primary end point of a phase 1/2 trial (NCT03149822), according to findings that were presented during the 2021 ASCO Annual Meeting.

Among 40 evaluable patients, the objective response rate (ORR) was 63.2% (95% CI, 0.485-1.00), which included a partial response rate of 50% (n = 3 of 6) in patients with non-clear cell RCC. The clinical benefit rate was 97.4% (95% CI, 0.88-1.00).

“Pembrolizumab and cabozantinib showed encouraging ORR in mRCC patients. Activity was seen in first- and subsequent-line settings and in clear cell RCC and non-clear cell RCC. This combination warrants further investigation,” lead study author Elizabeth R. Kessler, MD, an assistant professor of medical oncology at the University of Colorado Medicine, and co-authors wrote in the poster.

Checkpoint inhibitors and VEGF inhibitors are standard frontline treatments for patients with mRCC.

As such, the multisite, single-institution study evaluated the combination of pembrolizumab and cabozantinib in first and subsequent lines of therapy for patients with clear cell RCC and non-clear cell RCC.

The ORR at the RP2D served as the primary end point of the study.

Eligible patients had histological or cytological documentation of any histologic subtype of RCC, an ECOG performance status of 0 or 1, and measurable or evaluable disease based on RECIST version 1.1 criteria. Patients who had previously received pembrolizumab or cabozantinib were excluded, but prior treatment with other checkpoint inhibitors and VEGF inhibitors was allowed.

Patients with an active autoimmune disease on immunosuppression or who had experienced a grade 3 or greater adverse effect (AE) on prior treatment with a checkpoint inhibitor were also excluded.

Phase 1 results were presented during the 2019 Genitourinary Cancers Symposium. The present analysis included evaluable patients treated at the RP2D of 200 mg of intravenous pembrolizumab every 3 weeks plus 60 mg of oral cabozantinib daily from the phase 1 (n = 3) and phase 2 cohorts (n = 37).

Radiologic assessment was performed every 9 weeks. Treatment beyond RECIST progression in the setting of continued clinical benefit was allowed.

Baseline characteristics indicated that patients were a median age of 60.75 years. The majority of patients were male (60%) and had clear cell histology (85%), followed by non-clear cell (15%) and sarcomatoid (15%) histology. The majority of patients had prior nephrectomy (85%) and an intermediate International Metastatic RCC Database (IMDC) risk score (72.5%; poor IMDC, 12.5%).

Less than half of patients each received 0 (37.5%), 1 (40%), or at least 2 (15%) prior therapies. Prior treatment consisted of only a TKI in 43.5% of patients, immunotherapy in 42.5% of patients, and a TKI plus immunotherapy in 22.5% of patients.

Additional results indicated that the median progression-free survival was 10.4 months (95% CI, 6.3-not reached [NR]), and the median time to response was 18.1 weeks (95% CI, 17.1-NR).

Regarding safety, grade 1 or 2 treatment-related AEs (TRAEs) occurred in 98% of patients and included diarrhea (75%), dysgeusia (55%), fatigue (60%), hand-foot syndrome (33%), hypophosphatemia (48%), oral mucositis (53%), nausea/vomiting (58%), transaminitis (45%), thyroid abnormality (45%), and weight loss (63%).

Grade 3 to 5 TRAEs occurred in 47% of patients and included diarrhea (8%), fatigue (5%), hand-foot syndrome (3%), hypophosphatemia (20%), oral mucositis (5%), and transaminitis (8%).

A total of 28 patients required a dose reduction at a median of 4 cycles (range, 1-38). One grade 5 treatment-related event of reversible leukoencephalopathy syndrome occurred.

Other serious TRAEs included hypoglycemia, nephritis, pancreatitis, pneumonitis, pulmonary embolus, transaminitis, and stroke.

Reference

Kessler ER, Hu J, Srivastava G, et al. Phase I/II study of pembrolizumab and cabozantinib for metastatic renal cell carcinoma (mRCC). J Clin Oncol. 2021;39(suppl 15):4544. doi:10.1200/JCO.2021.39.15_suppl.4544

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Success with the 177Lu-PSMA-617 radioligand therapy would be transformative for the clear cell renal cell carcinoma treatment landscape.
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
“The therapy is designed to prevent both CAR T-cell inactivation and to restore the anti-tumor immunity of the white blood cells that have gotten through the tumor,” said Marasco, MD, PhD.
Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.
Investigators have found a way to reduce liver and biliary toxicity when targeting the molecule CAIX in patients with clear cell renal cell carcinoma.
Neoantigen-targeting vaccines resulted in an absence of recurrence in 9 patients with high-risk kidney cancer, according to David A. Braun, MD, PhD.
The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.
Wayne A. Marasco, MD, PhD, stated that by targeting 2 molecules instead of 1, higher levels of tumor cell killing can be achieved in patients with clear cell renal cell carcinoma.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content

Personalized kidney cancer vaccines may help guide immune therapies to more effectively attack cancerous cells while mitigating harm to healthy tissue.

Personalized Cancer Vaccines May Transform Treatment Options in Kidney Cancer

Roman Fabbricatore
July 25th 2025
Article

Personalized kidney cancer vaccines may help guide immune therapies to more effectively attack cancerous cells while mitigating harm to healthy tissue.


Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Advancements and Evolving Strategies in Breast Cancer Treatment at IBC East

Heather McArthur, MD, MPH;Erika P. Hamilton, MD;Hope S. Rugo, MD;Paolo Tarantino, MD, PhD
July 21st 2025
Podcast

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.


A genitourinary oncologist explained that KIM-1 can be used diagnose, risk-stratify, detect, and monitor disease treatment in patients with kidney cancers.

Analyzing Natural Killer Cell Restoration/KIM-1 Biomarker in Kidney Cancer

Roman Fabbricatore
July 24th 2025
Article

A genitourinary oncologist explained that KIM-1 can be used diagnose, risk-stratify, detect, and monitor disease treatment in patients with kidney cancers.


Unveiling Advances in GU Cancers: Insights from Oncology Decoded

Unveiling Advances in GU Cancers: Insights from Oncology Decoded

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;John Burke, MD;Dhaval R. Shah, MBBS
July 3rd 2025
Podcast

Dive into the latest in genitourinary oncology with "Oncology Decoded," featuring discussions on KEYNOTE-564 with RCC.


Neoantigen Vaccines Are Leading to a Personalized Frontier in RCC Immunotherapy

Neoantigen Vaccines Are Leading to a Personalized Frontier in RCC Immunotherapy

Ashling Wahner
July 20th 2025
Article

David A. Braun, MD, PhD, discusses how neoantigen vaccines are redefining RCC treatment, with the potential to activate potent, lasting T-cell activity.


CAR T-Cell Therapy to Target CAIX/CD70 Overexpression in ccRCC

CAR T-Cell Therapy to Target CAIX/CD70 Overexpression in ccRCC

Ashley Chan
July 19th 2025
Article

Researchers developed a CAR T-cell therapy to target CAIX/CD70 overexpression for patients with clear cell RCC.

Related Content

Personalized kidney cancer vaccines may help guide immune therapies to more effectively attack cancerous cells while mitigating harm to healthy tissue.

Personalized Cancer Vaccines May Transform Treatment Options in Kidney Cancer

Roman Fabbricatore
July 25th 2025
Article

Personalized kidney cancer vaccines may help guide immune therapies to more effectively attack cancerous cells while mitigating harm to healthy tissue.


Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Advancements and Evolving Strategies in Breast Cancer Treatment at IBC East

Heather McArthur, MD, MPH;Erika P. Hamilton, MD;Hope S. Rugo, MD;Paolo Tarantino, MD, PhD
July 21st 2025
Podcast

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.


A genitourinary oncologist explained that KIM-1 can be used diagnose, risk-stratify, detect, and monitor disease treatment in patients with kidney cancers.

Analyzing Natural Killer Cell Restoration/KIM-1 Biomarker in Kidney Cancer

Roman Fabbricatore
July 24th 2025
Article

A genitourinary oncologist explained that KIM-1 can be used diagnose, risk-stratify, detect, and monitor disease treatment in patients with kidney cancers.


Unveiling Advances in GU Cancers: Insights from Oncology Decoded

Unveiling Advances in GU Cancers: Insights from Oncology Decoded

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;John Burke, MD;Dhaval R. Shah, MBBS
July 3rd 2025
Podcast

Dive into the latest in genitourinary oncology with "Oncology Decoded," featuring discussions on KEYNOTE-564 with RCC.


Neoantigen Vaccines Are Leading to a Personalized Frontier in RCC Immunotherapy

Neoantigen Vaccines Are Leading to a Personalized Frontier in RCC Immunotherapy

Ashling Wahner
July 20th 2025
Article

David A. Braun, MD, PhD, discusses how neoantigen vaccines are redefining RCC treatment, with the potential to activate potent, lasting T-cell activity.


CAR T-Cell Therapy to Target CAIX/CD70 Overexpression in ccRCC

CAR T-Cell Therapy to Target CAIX/CD70 Overexpression in ccRCC

Ashley Chan
July 19th 2025
Article

Researchers developed a CAR T-cell therapy to target CAIX/CD70 overexpression for patients with clear cell RCC.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.